Labiotech.eu

News and Trends 12 Sep 2022

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

Clinical oncology company Ayala Pharmaceuticals, Inc. has announced updated, positive interim results from part A of its ongoing RINGSIDE pivotal phase 2/3 clinical trial evaluating investigational new drug AL102 in desmoid tumors. Ayala Pharmaceutical’s AL102 is a selective, oral gamma-secretase inhibitor. The data are being featured in an oral presentation at the European Society for […]

September 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

The first patient has been enrolled in a phase 3 study of a treatment for type 1A Charcot-Marie-Tooth Disease (CMT1A) in the U.S., it was announced today (September 12). Charcot-Marie-Tooth disease is a group of inherited conditions that damage the peripheral nerves and a treatment is being developed by French biopharmaceutical company, Pharnext. The PREMIER […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Reveal Genomics reveals more HER2DX breast cancer validation data

Reveal Genomics, S.L. says it has received more validation of HER2DX, the world’s first specialized genomic test for HER2+ breast cancer. Valentina Guarneri from the University of Padova presented the data at the European Society of Medical Oncology Congress 2022 in Paris, France. The data obtained from the analysis of tumor samples from the PerELISA […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

SiSaf Ltd, an RNA delivery and therapeutics company, has announced positive data confirming safety and efficacy of its Bio-Courier next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for autosomal dominant osteopetrosis type 2 (ADO2) siRNA therapy. The data was presented at the American Society of Bone and Mineral Research […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood pressure at optimal times throughout the day and night and was used in a study on hypertensive patients using a data set of more than […]

September 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Shasqi moves to phase 2 solid tumor study

Shasqi, a clinical-stage biotechnology company developing oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform says it has opened the phase 2 part of its phase 1/2a clinical study to further assess SQ3370 in anthracycline-naïve patients. The phase 2 study follows the company’s presentation at the European Society for Medical Oncology (ESMO) […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Liquid-interface assisted SERS could lead to earlier detection of Alzheimer’s

In a new publication in Opto-Electronic Advances, Japanese researchers discussed label-free trace detection of bio-molecules by liquid-interface assisted surface-enhanced Raman scattering (SERS) using a microfluidic chip. SERS has attracted attention in biotechnology. This is due to its high sensitivity to localized surface plasmon resonance of nanostructured metals. Trace detection of bio-molecules with large molecular weight […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Sep 2022

Fight against malaria boosted by findings from a vaccine trial showing high efficacy

Hope that malaria could be eradicated forever has been given a boost after new findings from a vaccine trial showed a high-rate of efficacy. Researchers from the University of Oxford and their partners have yesterday (September 8) reported new findings from their malaria vaccine R21/Matrix-M phase 2b trials following the administration of a booster dose. […]

September 9, 2022 - 4 minutesmins - By Liza Laws

Horizone Therapeutics, Eye disease, eye, eyes

News and Trends 9 Sep 2022

Improved vision with less eye injections for patients after primary endpoints met in trials

The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […]

September 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 9 Sep 2022

Beyond Biotech podcast 13: BioInnovation Institute, IASP

This week’s guests on the podcast are Bobby Soni, chief business officer at the BioInnovation Institute; and Harriet Edwards, International Association of Science Parks (IASP) media and community manager. We also have our weekly chat with global commercial real estate services company JLL, and this week it is with Travis McCready. IASP to host World […]

September 9, 2022

News and Trends 8 Sep 2022

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […]

September 8, 2022 - 2 minutesmins - By Liza Laws

CRISPR, CRISPR-Cas9, genome-editing, gene therapy

News and Trends 8 Sep 2022

CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded

Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September 8) they have a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field. In 2018, science and technology company Merck, of which Sigma-Aldrich is a subsidiary, announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based […]

September 8, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Ayala Pharmaceuticals presents interim data on desmoid tumor trial

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

Reveal Genomics reveals more HER2DX breast cancer validation data

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

Shasqi moves to phase 2 solid tumor study

Liquid-interface assisted SERS could lead to earlier detection of Alzheimer’s

Fight against malaria boosted by findings from a vaccine trial showing high efficacy

Improved vision with less eye injections for patients after primary endpoints met in trials

Beyond Biotech podcast 13: BioInnovation Institute, IASP

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!